Rigel Pharmaceuticals (RIGL) news
Recent news
Info Edge Board OKs ~INR 1B investment in unit 5IHL
Info Edge (India) Limited has approved an investment of approximately INR 1 billion in its subsidiary, 5IHL, as part of its strategic capital allocation plans. The investment, approved by the company’s board of directors, is intended to support the subsidiary’s operational requirements and to…
AInvest Wire · 2d agoKnight Therapeutics - Expects Tavalisse launch in Colombia in first half of 2027
Knight Therapeutics Inc. (TSX: GUD) has indicated that it expects to launch TAVALISSE® (fostamatinib disodium hexahydrate) in Colombia during the first half of 2027, according to regulatory and commercial timelines previously disclosed by the company. This follows the successful regulatory approval…
AInvest Wire · Sep 1, 2026Rigel Pharmaceuticals, Inc.: H.C. Wainwright raises target price to $85 from $57
On August 5, 2026, H.C. Wainwright revised its price target for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), raising it from $57 to $85, while maintaining its "Buy" rating . This update follows Rigel’s strong quarterly performance, where the biotechnology firm reported earnings of $0.88 per…
AInvest Wire · Aug 14, 2026Rigel Pharma 2Q total revenue $78.7M, est. $69.1M
AInvest Wire · Aug 4, 2026Rigel Pharma 2Q R&D expenses $14.0M, est. $12.7M
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.